An interventional study of Imigran and Isotonic Saline in Migraine Without Aura, sponsored by Danish Headache Center. Completed at 1 site in Denmark. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2020-06-22.
Sponsored by Danish Headache Center · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 18 studies in Migraine without Aura by Danish Headache Center — none open to participants now, none under way, none of them phase 3. Migraine without Aura · Danish Headache Center.
Among the 18 studies in Migraine without Aura by Danish Headache Center, this one is the 4th largest by enrollment of the 16 interventional ones that give a count, is one of 2 that started in 2018, is one of 15 with no phase, and was the 10th registered.
109 studies on the registry are indexed under Migraine without Aura; 18 are open to participants now.
Browse Migraine without Aura studies →None of the 18 studies in Migraine without Aura by Danish Headache Center is open now. The open studies under Migraine without Aura, anywhere →
Of the 12 Migraine without Aura studies recruiting now, 5 (42%) set no upper age limit and 7 (58%) stop at 75 or younger; 2 take children under 18; 2 take healthy volunteers.
This study: 18 Years to 60 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
18 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 2 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 37 is below the median of 87 across 87 interventional studies indexed under Migraine without Aura.
Median enrollment 28 across the 16 interventional studies, 56 across the 1 observational. Of the 15 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Danish Headache Center is the lead sponsor of 129 studies on the registry; 15 are open to participants now.
None of the studies under way reaches primary completion within a year.
Among the 18 studies in Migraine without Aura by Danish Headache Center, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The aim is to investigate the incidence of headache, migraine attacks and flushing after pituitary adenylate cyclase-activating peptide-38 (PACAP38) with and without treatment with sumatriptan in patients with migraine
Pituitary adenylate cyclase-activating peptide-38 (PACAP38) plays a role in migraine pathophysiology. Infusions of PACAP38 can trigger migraine-like attacks in some migraine patients and will induce flushing in all patients. We are investigating whether treatment with sumatriptan has an effect on the PACAP38-induced flushing and on whether headache and migraine is induced.
The purpose of this study is to investigate PACAP38-induced headache and migraine in patients with migraine who have been treated with either sumatriptan or placebo using purpose-developed standardized interview. The study will be conducted with a double-blind, placebo-controlled crossover study design.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Pituitary adenylate cyclase-activating peptide-38 infusion (10 picomol/kg/min) for 20 mins AND Imigran infusion (0.4 mg/min) for 10 mins
Drug: Imigran · Other: Pituitary adenylate cyclase-activating peptide-38
Pituitary adenylate cyclase-activating peptide-38 infusion (10 picomol/kg/min) for 20 mins AND Isotonic saline for 10 mins (placebo)
Other: Isotonic Saline · Other: Pituitary adenylate cyclase-activating peptide-38
All patients will undergo this intervention on one of two study days
Also known as: Sumatriptan
All patients will undergo this intervention on one of two study days
All patients will undergo this intervention on both study days
Also known as: PACAP38
Incidence of migraine
Incidence of migraine after PACAP38-infusion will be estimated through a standardized interview based on the international headache classification for migraine
Time frame: From 0 to 12 hours after infusion
Effect of Sumatriptan
Severity of PACAP38-induced headache and migraine after pretreatment with sumatriptan in migraine patients measured by numerical rating scale for pain from 0 ("no pain") to 10 ("worst pain imaginable")
Time frame: From 0 to 12 hours after infusion
Severity of flushing
Facial skin blood flow (flushing) will be measured by laser doppler flowmetry to evaluate the severity of PACAP38-induced flushing with and without sumatriptan-treatment
Time frame: From 0 to 4 hours after infusion
Facial temperature
PACAP38-induced temperature changes with and without sumatriptan-treatment measured by infrared thermography
Time frame: From 0 to 4 hours after infusion
Superficial temporal artery diameter
Superficial temporal artery diameter after PACAP38 with and without sumatriptan-treatment measured by ultrasound
Time frame: From 0 to 4 hours after infusion
Severity of headache
Severity of PACAP38-induced headache will be rated on a numerical rating scale for pain from 0 ("no pain") to 10 ("worst pain imaginable")
Time frame: From 0 to 12 hours after infusion
Plan to share: No
Ran from Jul 2018 to primary completion in Dec 2019, 16 months.
Of 29 non-industry interventional studies with no phase under Migraine without Aura, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 34. This study's 16 months is below that.
Counting every sponsor, half of 33 studies reached it within 19 months; a quarter within 12 and three quarters within 34.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Sumatriptan